In a recent interview, Dr. Lecia V. Sequist, a member of the team behind the Sybil AI algorithm, discusses how technology may soon be able to predict who will develop lung cancer. Read more
During the European Lung Cancer Congress, Dr. Natalia Valdiviezo presented the data, which favored frontline osimertinib plus chemotherapy compared to osimertinib alone for patients with EGFR-mutated NSCLC. Read more
In light of data from FLAURA2 and MARIPOSA, Drs. Suresh Ramalingam and Joshua Sabari weighed the pros and cons during the 2024 TTLC meeting. Read more
During a recent debate, Drs. Anne Chiang and Stephen Liu offered differing perspectives on the feasibility of biomarker use in the small-cell lung cancer space. Read more
Surgeon Erin Gillaspie, MD, said surgery still has a role in the treatment of mesothelioma while medical oncologist Hedy Kindler, MD, said newer systemic therapies make surgery obsolete in this space. Read more
Dr. Mark Kris, who leads the IASLC Pathologic Response Project, recently provided an update on efforts to collect data to confirm whether pathologic complete response can predict long-term outcomes. Read more
Drs. Umberto Malapelle, Jarushka Naidoo, Isabelle Opitz, and Noemí Reguart will lead WCLC when it returns to Barcelona September 6-9, 2025. Read more
The 2024 World Conference on Lung Cancer may still be months away, but with deadlines approaching, now is the time to submit scientific abstracts and applications for the JTO manuscript reviewer workshop. Read more
According to research presented during the North America Conference on Lung Cancer, moving away from pack-years of smoking history to duration of smoking history would increase the number of Black patients who qualify for screening to a rate comparable to that of white patients. Read more
During the 2023 World Conference on Lung Cancer, Dr. Stephen Chun said long-term data show intensity-modulated radiation therapy offers an overall survival benefit and reduced toxicity compared to 3D conformal radiation therapy. Read more